Chabner Colloquium and 2017 STO Annual Meeting
Session 1:
New Insights into DNA Repair and Drug Response
Targeting the ATR Kinase in Cancer Therapy
Lee Zou, PhD
Lecture: Audio|Slides
PARP Inhibitor Resistance and Acquired Vulnerability in Ovarian Cancer
Alan D’Andrea, MD
Assessing DNA Repair in Clinical Trials
Ted Hong, MD
Lecture: Audio|Slides
Session 2:
Targets That Defy Effective Therapy
Developing Therapies for Ras-driven Cancers
Karen Cichowski, PhD
Lecture: Audio|Slides
Is FGFR Inhibition an Effective Target in Gastrointestinal Tumors?
Lipika Goyal, MD
Lecture: Audio|Slides
Intergenic Fusions in Advanced HR+ Breast Cancer
Leif Ellisen, MD, PhD
Lecture: Audio
Session 3:
Promising Drug-antibody Conjugates and Cell Death Pathway Inhibitors
Genomic and Functional Characterization of Patient Derived Xenograft Models of Small Cell Lung Cancer
Anna Farago, MD, PhD
Lecture: Audio|Slides
Antibody Drug Conjugates for Triple Negative Breast Cancer: Targeting Positive in the Negative
Aditya Bardia, MD, MPH
Lecture: Audio|Slides
PARP in Breast Cancer
Steven J. Isakoff, MD, PhD
Lecture:Audio|Slides
Session 4:
Junior Faculty Forum
Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor
Spheroids
Russell Jenkins, MD, PhD
Lecture: Audio|Slides
Financial Toxicity of Cancer
Ryan Nipp, MD, MPH
Lecture: Audio|Slides
Improving Therapy for EGFR-Mutant Lung Cancers
Zosia Piotrowska, MD
Lecture: Audio|Slides
2017 Acknowledgments
The Society for Translational Oncology gratefully acknowledges support of this activity from:
Amgen
EcoR1 Capital
Lilly
Novartis
Pfizer